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Human resistin is a cytokine that induces low-grade
inflammation by stimulating monocytes. Resistin-
mediated chronic inflammation can lead to obesity,
atherosclerosis, and other cardiometabolic diseases.
Nevertheless, the receptor for human resistin has not
been clarified. Here, we identified adenylyl cyclase-
associated protein 1 (CAP1) as a functional receptor
for human resistin and clarified its intracellular
signaling pathway to modulate inflammatory action
of monocytes. We found that human resistin directly
binds to CAP1 in monocytes and upregulates cyclic
AMP (cAMP) concentration, protein kinase A (PKA)
activity, andNF-kB-related transcription of inflamma-
torycytokines.OverexpressionofCAP1 inmonocytes
enhanced the resistin-induced increased activity of
the cAMP-dependent signaling. Moreover, CAP1-
overexpressed monocytes aggravated adipose tis-
sue inflammation in transgenic mice that express
human resistin from their monocytes. In contrast,
suppression of CAP1 expression abrogated the resis-
tin-mediated inflammatory activity both in vitro and
in vivo. Therefore, CAP1 is the bona fide receptor for
resistin leading to inflammation in humans.
INTRODUCTION
Resistin was first identified as a mediator of insulin resistance in
obese mice (Steppan et al., 2001). It is secreted from mature484 Cell Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc.adipocytes in rodents, and a few studies have implicated murine
resistin in the pathogenesis of obesity-mediated insulin resis-
tance and type 2 diabetes (Li et al., 2009; Nakata et al., 2007;
Steppan et al., 2001). However, human resistin is quite different
from murine resistin. Human resistin is primarily expressed in
and secreted frommonocytic cells (Patel et al., 2003). Moreover,
the function of resistin in insulin resistance and obesity remains
inconclusive in humans (McTernan et al., 2002; Savage et al.,
2001; Utzschneider et al., 2005). Interestingly, human resistin
seems to be involved in the recruitment of other immune cells
and in the secretion of proinflammatory factors (Bokarewa
et al., 2005; Silswal et al., 2005), and increasing evidence links
resistin with inflammation and atherogenesis (Burnett et al.,
2005; Jung et al., 2006; Reilly et al., 2005). As we reported previ-
ously (Cho et al., 2011), resistin directly aggravates atheroscle-
rosis by stimulating monocytes to induce vascular inflammation.
In terms of the increasing role for inflammation in metabolic dis-
ease, the receptor and its intracellular signaling of resistin in
human monocytes can be the therapeutic target of chronic
inflammation leading to cardiometabolic disease.
Although the inflammatory functions of human resistin appear
to be regulated by activation of the NF-kB transcription factor
(Silswal et al., 2005), understanding the biological function of
human resistin has been slowed by lack of information about
its corresponding receptor and signaling mechanisms. Recent
reports have suggested an isoform of decorin (Daquinag
et al., 2011), mouse receptor tyrosine kinase-like orphan recep-
tor 1 (ROR1) (Sa´nchez-Solana et al., 2012), and Toll-like recep-
tor 4 (TLR4) (Tarkowski et al., 2010) as potential receptors for
resistin. However, both decorin and ROR1 are only putative re-
ceptors for murine resistin, and none of these have been shown
to mediate the inflammatory effects of resistin in humans.
In addition, there was no evidence of the direct interaction
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binding assay.
Here, we report the identification of adenylyl cyclase-associ-
ated protein 1 (CAP1) as a protein that directly binds to human
resistin and elicits inflammatory effects in cultured humanmono-
cytes and in white adipose tissue (WAT) in humanized resistin
mice in vivo. The gain- and loss-of-function studies implicate
CAP1 as a bona fide functional receptor for human resistin.
RESULTS
Identification of a Human Resistin Binding Protein
Human resistin was conjugated with the Fc region of mouse
immunoglobulin (denoted as mFc-hResistin) to detect potential
receptor proteins using immunoaffinity methods (Figure 1A).
The amino terminus of resistin was selected for conjugation
with mFc (Figure 1B) because resistin molecules exist as multi-
meric complexes of coiled-coil trimers that form tail-to-tail hex-
amers via disulfide bonding near their amino termini (Patel
et al., 2004). We hypothesized that the carboxy-terminal globular
region constitutes the receptor binding site of resistin, similar to
what has been observed for the adiponectin globular domain
(Yamauchi et al., 2003).
The mFc-hResistin fusion was expressed and purified to ho-
mogeneity after transfectingmFc-hResistin DNA into human em-
bryonic kidney 293F (HEK293F) cells. The western blot analysis,
which was performed in nonreducing condition during purifica-
tion, indicated that the purifiedmFc-hResistin forms amultimeric
assembly, not a monomer (Figure 1C).
Through western blots using the multimeric mFc-hResistin as
a ligand (or a primary antibody) to human monocytic leukemia
(THP-1) cell lysate, we were able to identify a protein with a
molecular mass of about 55 kDa (Figure 1D). This protein nearly
disappeared in the presence of an abundant non-Fc-conjugated
recombinant human resistin protein (rhResistin) (Figure 1E). Also,
whenwe used just recombinant Fc as a primary antibody instead
of Fc-hResistin, we could not detect any protein (Figure 1F).
These findings suggested that THP-1 cells expressed a 55 kDa
sized protein capable of specifically binding with human resistin.
To identify the 55 kDa molecule, which we believed to be a
receptor for human resistin, we incubated the purified mFc-
hResistin with THP-1 cell lysates and then repurified mFc-
hResistin by immunoprecipitation using mFc-specific beads.
As expected, SDS-PAGE chromatography detected a specific
band corresponding to a protein of approximately 55 kDa (Fig-
ure 1G). Then, we excised the gel band and performed MALDI-
TOF (Figure 1H). This analysis identified the binding protein as
CAP1 (NCBI accession number Q01518). Figure S1 (available
online) depicted the full amino acid sequence of CAP1 in
Homo sapiens and the sequences of matched peptides profiled
by MALDI, as shown with underlining and bold face.
CAP1 Characterization
HumanCAP1 is an actin-binding protein of 475 amino acids, with
a molecular mass of 51.9 kDa. CAP1 was originally isolated as a
component of the Saccharomyces cerevisiae adenylyl cyclase
complex (Field et al., 1990), and it is highly conserved from yeast
to humans (Matviw et al., 1992). In yeast, the CAP1 homolog
plays a key role in the cyclic AMP (cAMP) pathway. We analyzedCethe expression of CAP1 mRNA in various human cell lines and
multiple organ tissues of rabbits and transgenic mice expressing
macrophage-specific human resistin, compared to that of
general C57BL/6 mice (Figure 2A). In our previous study (Cho
et al., 2011), rabbits, rather than general mice, served as an
established model for studying the physiology of human resistin.
The CAP1 gene was detectable in most tissues but enriched
in peripheral blood mononuclear cells (PBMCs) and bone
marrow. The expression pattern of CAP1 was similar to that of
resistin (Figure 2A), particularly in human cells, rabbits, and the
transgenic mice, which is consistent with the hypothesis that
both molecules contribute to inflammatory processes in human
monocytes.
While CAP1 was considered to be a cytoplasmic protein in
Dictyostelium discoideum, CAP1 is localized near the plasma
membrane of resting cells (Noegel et al., 1999). Recently,
CAP1was found to bemainly associatedwith plasmamembrane
in human THP-1 cells (Wakeel et al., 2009). Indeed, we were able
to detect CAP1 not only in the cytosol, but also in the membrane
fraction of THP-1 cells by western blotting (Figure 2B). Also, we
found that the exogenously applied resistin elicited a change in
CAP1 localization to membrane surface (Figures 2B and 2C).
Furthermore, the coimmuneprecipitation assay demonstrated
the direct binding interaction between resistin and CAP1, partic-
ularly in the membrane fraction and the cytosolic fraction of
THP-1 cells (Figure 2D). Through double immunofluorescent
staining of THP-1 cells treated with rhResistin using antibodies
against resistin and CAP1, the strongest colocalization was
observed between resistin and CAP1, which exhibited similar
distribution and fluorescence intensity around the cell mem-
brane (Figure 2E).
Human Resistin Binds Directly to CAP1
To address whether resistin binds directly to CAP1, whole-cell
extracts of THP-1 cells were immunoprecipitated with anti-
hCAP1, immunoblotted with anti-hResistin, and vice versa. We
observed coimmunoprecipitation of human resistin and CAP1
in THP-1 (Figure 3A). Also, we performed a far western analysis
(Wu et al., 2007) to confirm the interaction between resistin
multimer and CAP1 in vitro. Briefly, purified mFc-hResistin was
transferred to a nitrocellulose membrane, as in standard western
blotting, but in nonreducing condition. The membrane then
was blocked and incubated with recombinant human CAP1
(rhCAP1). This approach identified CAP1 on spots in the mem-
brane corresponding to the multimeric assembly of mFc-
hResistin (Figure 3B), demonstrating that the resistin multimer
and CAP1 interact directly. Further, we performed a bimolecular
fluorescence complementation (BiFC) assay, which is based on
complementation between two nonfluorescent fragments of the
fluorescent protein when they are brought together by interac-
tion between proteins fused to each fragment (Hu et al., 2002).
Using this nonimmunoglobulin binding approach, we could visu-
alize the interaction between human resistin and CAP1 in living
cells (Figure 3C).
In addition, we performed a classical fluorescence-activated
cell sorting (FACS)-based binding assay. First, the purified multi-
meric human resistin was fluorescently labeled, and then we
analyzed the binding of the labeled resistin to THP-1 cells, either
overexpressed or lacking CAP1. Resistin-binding cells werell Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc. 485
Figure 1. Identification of a Human Resistin Binding Protein
(A) As a first step to detect putative resistin receptor(s), we cloned an mFc-conjugated hResistin fusion protein (mFc-hResistin).
(B) Schematic construct of mFc-hResistin shows that the mFc region was conjugated at the N terminus of human resistin.
(C) The expression and purification of mFc-hResistin were confirmed by western blotting with an anti-mFc-HRP antibody and by Coomassie staining,
respectively. Western analysis in nonreducing condition indicates that the purified mFc-hResistin forms a multimeric assembly, not a monomer.
(D–F) Through western blotting, we applied mFc-hResistin as a primary antibody to human monocytic leukemia (THP-1) cell extracts and identified an
approximately 55 kDa protein that bound specifically to mFc-hResistin (red arrow) (D), which was not detectable after blocking the membrane with non-Fc-
conjugated recombinant human resistin (E) or using control recombinant Fc as a primary antibody instead (F).
(G) Representative immunoprecipitation findings. The incubation mixture of mFc-hResistin and THP-1 cell extracts was precipitated using mFc-specific beads.
The red arrow indicates a putative human resistin receptor at approximately 55 kDa.
(H) Schematic respresentation of the methodology used to identify the 55 kDa sized putative receptor protein. After the immunoprecipitation and gel electro-
phoresis, we excised the gel band and performed mass spectrometric analysis to identify the receptor protein as adenylyl cyclase-associated protein 1 (CAP1).
See also Figure S1.
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control group or CAP1-downregulated cell group (Figure 3D).
Moreover, a competitive FACS assay further validated the direct
interaction, demonstrating that the binding can be effectively
competedwith nonlabeled resistin (Figure 3E). As another recep-
tor-binding competition assay, rhCAP1 was dispensed into486 Cell Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc.ELISA plates and incubated with mFc-hResistin, in which bind-
ing had been quantitated by fluorescence before and after
incubation with excessive unconjugated rhResistin. As shown
in Figure 3F, mFc-hResistin was displaced by the recombinant
protein in a dose-responsive manner, and the competitive
binding curve showed that recombinant resistin competed with
Figure 2. CAP1 Characterization
(A) The expression of CAP1 mRNA in various human cell lines and multiple organ tissues of rabbits and humanized resistin mice (transgenic mice with
macrophage-specific expression of human resistin) compared to general C57BL/6 mice. RT-PCR of resistin in various tissues indicated robust expression of
CAP1 and resistin in peripheral blood mononuclear cells (PBMCs). The error bars represent SEM.
(B) Representative western blotting detecting human CAP1 in the membrane fraction of human monocytic leukemia (THP-1) cells as well as cytosol. Importantly,
the exogenously applied resistin elicited a change in CAP1 localization to membrane surface.
(C) Also, the surface flow cytometric analyses (FACS) demonstrated that the number of membrane CAP1-positive cells was increased significantly after the
stimulation with Fc-hResistin (n = 3, *p < 0.001). The error bars represent SEM.
(D) Coimmunoprecipitation of human resistin and CAP1 in the membrane fraction as well as in the cytosolic fraction of THP-1 cells.
(E) Colocalization of human resistin and CAP1 as determined by immunofluorescence double staining in THP-1 cells. Scale, 10 mm. HUVEC, human umbilical vein
endothelial cells; HepG2, human hepatocellular liver carcinoma cells; HDF, human dermal fibroblasts; WAT, white adipose tissue; hCAP1, human CAP1;
hResistin, human resistin; Fc-hResistin, mFc-conjugated human resistin fusion protein.
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Identification of a Human Resistin ReceptormFc-hResistin for CAP1 binding (half maximal effective concen-
tration [EC50] = 0.784 mM; calculated EC50 is likely related to
the KD). To calculate EC50, we assumed a one-site receptor-
ligand binding model and applied the Cheng-Prusoff equation
(Cheng and Prusoff, 1973) using GraphPad Prism.CeFinally, we underwent a direct binding assay using rhResistin
and rhCAP1 (Figure 3G). The binding curves showed increased
response unit (RU) between hResistin and hCAP1 in a dose-
dependent manner. The calculated dissociation equilibrium con-
stant (KD) from the dissociation curves was 0.078 mM. Thesell Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc. 487
Figure 3. Human Resistin Binds Directly to CAP1
(A) Representative coimmunoprecipitation of human resistin and CAP1.
(B) Representative far western blot of multimeric mFc-hResistin and recombinant human CAP1 (rhCAP1).
(C) Representative bimolecular fluorescence complementation (BiFC) assay visualizing the human resistin-CAP1 interaction in living cells. The highest fluo-
rescence intensity was exhibited when both CAP1 and resistin fused to each fragment (pVC155, pVN173) were expressed (left panel). However, when human
CAP1 was expressed alone, detectable fluorescence was not exhibited (middle panel). When SH3- and actin-binding domain deletion mutant was cloned into
pVC155 instead of wild-type CAP1 and coexpressed with pVN173-hResistin fusion protein, detectable fluorescence was not exhibited (right panel).
(D) Representative classic background flow cytometry analysis (FACS)-based binding assay. PE-hResistin-binding cells were increased in the CAP1 upregulated
cell group more than those in control or CAP1 downregulated cell groups.
(E) Competitive FACS binding assay. FITC-Fc-hResistin was displaced by the nonlabeled rhResistin in a dose-dependent manner (n = 3; *p < 0.001, yp < 0.01).
The error bars represent SEM.
(F) Competitive ELISA binding assay. Recombinant human resistin (rhResistin) bound to rhCAP1 and was competitively inhibited by mFc-hResistin (n = 3;
*p < 0.001). The error bars represent SEM.
(G) Direct binding assay between human resistin and CAP1.
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action between hCAP1 and hResistin.
Signaling Pathway of Resistin via CAP1
Because CAP1 is known to play a role in adenylyl cyclase activa-
tion, the finding that resistin binds to CAP1 suggests that resistin
might activate adenylyl cyclase. As expected, the ELISA showed
that resistin significantly increased cAMP levels in THP-1 cells
(Figure 4A). Consistent with this, resistin increased the activities
of both PKA and NF-kB in THP-1 cells (Figure 4B) and subse-
quently upregulated the mRNA and protein levels of inflamma-
tory cytokines such as interleukin-6 (IL-6), tumor necrosis factor
alpha (TNF-a), and IL-1b (Figure 4C).
The cellular responses to resistin were greater when this mole-
cule was introduced via adenoviral gene transfection than when
cells were directly exposed to recombinant resistin protein (Fig-
ure 4B), perhaps reflecting the many cysteine residues in resistin
leading to formation of the disulfide-dependent multimeric struc-
ture (Aruna et al., 2003; Patel et al., 2004; Raghu et al., 2004) that
is active and easily formed by adenoviral transfection but formed
in difficulty by treatment with the recombinant protein form.
Nonreducing SDS gel analysis of cell lysates transfected with
adenovirus-delivered resistin identified the resistin protein in
fractions corresponding to molecular masses of approximately
50 kDa and 20 kDa (Figure S2). These likely represented the re-
sistin trimer and dimer forms (Aruna et al., 2008; Gerber et al.,
2005).
Since resistin induces cytokine expression via the activation of
NF-kB (Silswal et al., 2005), we hypothesized that this activation
may be downstream of adenylyl cyclase activation. Though
unusual, this order would be consistent with reports of crosstalk
between cAMP/PKA signaling and proinflammatory NF-kB
pathways in macrophages (Peters-Golden, 2009; Wall et al.,
2009). Indeed, treatment of THP-1 cells with PKA inhibitors
blocked resistin-induced NF-kB activation and cytokine expres-
sion (Figure 4C).
To determine whether CAP1 is a functional signaling receptor
for human resistin, we manipulated CAP1 expression and evalu-
ated its impact on intracellular signals and proinflammatory
actions of resistin in monocytes in vitro. CAP1 levels were
reduced using specific small interfering RNAs (siRNAs) in
THP-1 cells (Figure 4D). CAP1 knockdown inhibited the ability
of resistin to increase cAMP concentration (Figure 4E), PKA,
NF-kB activity (Figure 4F), and cytokine production (Figure 4G).
Conversely, overexpression of CAP1 by adenoviral transfection
(Figure 4H) enhanced the intracellular signals and biological re-
sponses of THP-1 cells to resistin, including increased PKA,
NF-kB activity (Figure 4I), and cytokine expression (Figure 4J).
Resistin-Binding Domain of CAP1
CAP1 is comprised of three major structurally and functionally
distinct domains (Figure 5A). The highly conserved carboxy-
terminal domain of CAP1 binds to monomeric actin and is
necessary for normal cellular morphology. The centrally located
proline-rich domain interacts with Src homology 3 (SH3) do-
mains of specific proteins, including the yeast actin-associated
protein Abp1p (Freeman et al., 1996; Lila and Drubin, 1997).
Finally, the amino-terminal domain of CAP1 interacts with
adenylyl cyclase in yeast. In higher eukaryotes, however, theCefunction of the CAP1 N terminus is unknown. The amino termini
of CAP1molecules can interact with each other or with the CAP1
carboxyl terminus, suggesting the possibility of either parallel or
antiparallel dimers (Hubberstey and Mottillo, 2002). Notably,
either dimer topology could allow the polyproline SH3-interact-
ing domain to bind target proteins.
We cloned three deletion mutants of human CAP1 using lenti-
viral vectors (Figure 5B): an adenylyl cyclase binding domain
deletion mutant (DAC binding domain [BD] deletion), a mutant
in which both the SH3 binding domain and the actin binding
domain were deleted (DSH3Dactin BD deletion), and an actin
binding domain deletion mutant (Dactin BD deletion). Following
resistin stimulation, PKA/NF-kB signaling (Figure 5C) and inflam-
matory cytokine production (Figure 5D) were not affected in the
Dactin BD deletion mutant overexpressed cells, whereas they
were suppressed in the DAC BD deletion and in the DSH3Dactin
BD deletion mutant overexpressed cells. These data indicate
that the actin binding domain of CAP1 is not necessary for the re-
sistin ligand binding and/or receptor signaling, whereas the other
two domains are crucial. Further, to identify the exact resistin
binding sites on CAP1, we performed in vitro binding assays be-
tween each CAP1 mutant and rhResistin. After overexpressing
His-tagged CAP1 mutants in 293A cells and treating rhResistin,
we immunoprecipitated the whole-cell extracts with His anti-
bodies. Then, samples were western blotted using antibodies
against both resistin and His. The band at approximately
12 kDa corresponding to rhResistin was not detectable in the
DSH3Dactin BD deletion mutant, whereas it was detected in
the DAC BD deletion mutant and in the Dactin BD deletion (Fig-
ure 5E). These observations confirm that human resistin binds to
CAP1 via the proline-rich SH3 BD and that the AC domain likely
plays a key role in receptor signaling.
Neither X-ray crystallography nor nuclear magnetic resonance
spectroscopy data are available to deduce the molecular struc-
ture of CAP1. Thus, we predicted the structure of the resistin-
binding domain using homology modeling (Fernandez-Fuentes
et al., 2007; Sternberg et al., 1999) with the known structure of
cytidylyltransferase from Thermus thermophilus HB8 (2PX7),
which has 20% sequence identity and 32% sequence homology
with the region of CAP1 (Figure S3A). Using Discovery Studio 2.5
(Accelrys), we were able to visualize the predicted structure of
the resistin-binding domain and the known structures of the re-
sistin trimer (Patel et al., 2004). Then, to predict the structure of
the resistin-CAP1 complex, we virtually analyzed the surface
geometry of the complex using a protein-protein docking simu-
lation and the score function analysis. Using the Pairwise Shape
Complementarity function-based docking algorithm, ZDOCK
(Chen et al., 2003; Chen and Weng, 2003), we inferred several
3D binding structures between the resistin trimer and the resis-
tin-binding domain of CAP1. Then, we evaluated the binding
free energy of each complex using the Poisson-Boltzmann sur-
face area method (Zoete et al., 2010). Figure 5F depicts the
structure of the resistin trimer-CAP1 binding complex with the
lowest binding free energy, which could be the conformation
observed in nature. Further, we performed molecular dynamics
(MD) simulations for predicting the binding energy between re-
sistin and mutated CAP1. We found that the point mutations in
CAP1-SH3 BD abolish interaction between resistin and CAP1-
SH3 BD. As shown in Figure 5F (magnified circle), hydrophobicll Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc. 489
Figure 4. Resistin Signaling Pathway via CAP1
(A) cAMP concentration was increased with the treatment of a physiologic dose (50 ng/ml) of recombinant human resistin in THP-1 cells. (n = 3; yp < 0.01,
zp < 0.05).
(B and C) Both recombinant protein resistin (rhRe; 50 ng/ml) and gene-transfected resistin (adv-hRe) increased the activities of PKA andNF-kB significantly (n = 3;
*p < 0.001, yp < 0.01, zp < 0.05) (B) and subsequently induced inflammatory cytokines at the mRNA and protein levels (C). The PKA inhibitor, KT5720, abolished
resistin-induced NF-kB activation and inflammatory cytokine expression (n = 3; *p < 0.001, yp < 0.01, zp < 0.05).
(D–G) CAP1 levels were reduced using specific small interfering RNAs (siRNAs) in THP-1 cells (D). siRNA targeting CAP1 abolished resistin-induced increases in
cAMP concentration (E), PKA and NF-kB activities (F), and cytokine production (G) (n = 3; *p < 0.001, yp < 0.01, zp < 0.05).
(H–J)We overexpressed humanCAP1 in THP-1 cells using adenovirus (H), which enhanced the intracellular signals (I) and biological effects (J) of resistin in THP-1
cells. The expression data were quantified using real-time qPCR, and the mRNA expression of cytokines was validated by ELISA (n = 3; *p < 0.001, yp < 0.01,
zp < 0.05). The error bars represent SEM. See also Figure S2.
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Figure 5. Resistin-Binding Domain of CAP1
(A and B) Schematics of three major domains (A) and three deletion mutants (B) of human CAP1.
(C) Representative western blotting shows resistin-induced PKA/NF-kB signaling following overexpression of each of three CAP1 mutants in THP-1 cells.
(D) Resistin-induced inflammatory cytokine production following overexpression of each of three CAP1 mutants in THP-1 cells (n = 3 for each mutant; *p < 0.001,
yp < 0.01). The error bars represent SEM.
(E) In vitro binding assays between each CAP1mutant and rhResistin. Binding of resistin and CAP1 (bottom row) was decreased significantly when samples were
incubated with mutants deleted for the SH3 domain.
(F) Predicted secondary structures of the resistin trimer-CAP1 SH3 binding domain complex. The resistin trimers are shown as grey, cyan, and orange schematic
ribbons. The CAP1-SH3 binding domain is shown as a dark green ribbon. The detailed interactions are illustrated in the magnified white circle. We targeted Val27
and Ser28 in the CAP1-SH3 binding domain to induce point mutations and substitute glycine for Val27 and Ser28. See also Figure S3.
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of Val27 in CAP1-SH3 BD and Trp82A, Trp82C in the resistin
trimer. Also, the hydrogen bonds between Ser28 in CAP1-SH3
BDand Ser64A, Ser60C in the resistin trimer increase the binding
affinity. So, we targeted Val27 and Ser28 in CAP1-SH3 BD to
induce point mutations and substitute glycine for Val27 andCeSer28. After 2 ns of MD simulations, we calculated the difference
of binding free energy between the wild-type complex and
mutant complex. The wild-type CAP1 is predicted to bind
more favorable than its mutant, with 9.0 kcal/mol. It suggests
that substituting glycine for Val27 and Ser28 in CAP1-SH3 BD
may abolish interaction between resistin and CAP1-SH3 BD.ll Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc. 491
Figure 6. CAP1 and Migration Activity of Monocytes
(A) Vertical collagen gel invasion assay. Monocytes overexpressing CAP1 migrate toward resistin significantly more frequently than did those with CAP1
downregulated (n = 3; *p < 0.001). Scale, 500 mm.
(B) Transwell migration assay. Overexpressing DSH3Dactin BD deletion or Dactin BD deletion CAP1 mutant inhibited the resistin-mediated infiltration of
monocytes (n = 3; *p < 0.001, yp < 0.01).
(C and D) We suppressed human decorin, TLR4, and ROR1 expression in human monocytes (C), and they showed little effect on resistin-induced proin-
flammatory cytokine production (D) (n = 3; *p < 0.001, yp < 0.01, zp < 0.05; ns, not significant).
(E) Also, human decorin, TLR4, and ROR1 did not affect the migration of human monocytes toward human resistin (n = 3; yp < 0.01; ns, not significant). The error
bars represent SEM. See also Figure S4.
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We previously demonstrated that resistin has chemoattractive
effects on monocytes (Cho et al., 2011). Using the same assay
of vertical collagen gel invasion (Cho et al., 2011; Hur et al.,
2007; Yoon et al., 2005), in the present study we show that
adenovirus-mediated CAP1 overexpression significantly en-
hanced the invasion of human THP-1 cells toward resistin (Fig-
ure 6A). In contrast, suppression of CAP1 expression by short
hairpin RNAs (shRNAs) abrogated the resistin-mediated infiltra-
tion of monocytes (Figure 6A). These data indicate that the
chemotaxis of macrophages or THP-1 cells to resistin is depen-
dent upon CAP1. Further, for evaluating the role of the actin BD
on chemotaxis, we performed the transwell migration assay by
comparing wild-type CAP1 with the deletion mutants of CAP1.
Interestingly, the migration ability of THP-1 cells was not
changed significantly inDACBDdeletionmutant group, whereas
overexpressing the DSH3Dactin BD deletion or Dactin BD
deletion CAP1 mutant inhibited the resistin-mediated infiltration492 Cell Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc.of monocytes (Figure 6B). Thus, the actin binding domain of
CAP1 might have a pivotal role on the resistin-related migration
activity of human monocytes.
In addition, to demonstrate that CAP1 is indeed the bona fide
receptor of human resistin, we assessed the role of the three
previously reported receptors in the inflammatory actions of
monocytes induced by human resistin. After suppressing the
expression of human decorin, ROR1, and TLR4 using specific
shRNAs (Figure 6C), we found that the expression levels of
human decorin, ROR1, and TLR4 in human monocytes had little
effect on the production of proinflammatory cytokines that was
stimulated by human resistin (Figure 6D). Transwell migration
assay also demonstrated that human decorin, ROR1, and
TLR4 did not affect the migration of human monocytes toward
human resistin (Figure 6E). Only CAP1 had a great effect on
the production of proinflammatory cytokines and the infiltration
property of human monocytes that were induced by human
resistin. When compared to CAP1 expression, moreover, both
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particularly in human PBMCs or THP-1 (Figures S4A and S4B).
Even if resistin was applied exogenously or using viral transfec-
tion, the expression levels of decorin and ROR1 were not
increased (Figure S4C).
In Vivo Analysis of Resistin-CAP1 Interaction
Mice humanized by expressing human resistin in monocytes/
macrophage lineage were known to develop an exacerbation
of inflammation in the WAT when fed with a high-fat diet (Qata-
nani et al., 2009). Before starting animal experiments using these
transgenic mice (humanized resistin mice), we addressed evi-
dence of the interaction between human resistin and murine
CAP1 (Figure S5). Murine CAP1 was known to have 97% homol-
ogy with human CAP1, although its function was rarely known in
both species so far (Hubberstey and Mottillo, 2002). Finally, we
evaluated whether alteration of CAP1 expression in the mono-
cytes of humanized resistin mice affects resistin-induced WAT
inflammation. The time course of the in vivo experiments is illus-
trated in Figure 7A.
Following a 1-month period of a high-fat diet to induce WAT
inflammation, interestingly, CAP1 expression was elevated in
WAT of humanized resistin mice along with human resistin and
monocyte chemotactic protein-1 (MCP-1) (Figure 7B). Conse-
quently, humanized resistin mice exhibited an accumulation of
CAP1-overexpressed macrophages in the WAT greater than
that of control mice (Figure 7C). However, when CAP1-sup-
pressed monocytes were administered into humanized resistin
mice, the accumulation of macrophages in WAT decreased
significantly (Figure 7C). This effect was concordant with a
reduction in several inflammatory markers, including TNF-a
(Figure 7D). The identity of the infiltrating macrophages in WAT
was confirmed by immunofluorescence staining, which indi-
cated that the infused monocytes migrated to inflamed WAT
and that monocytes overexpressing CAP1 infiltrated WAT to
an extent much greater than did CAP1-suppressed monocytes
(Figure 7E). These findings strongly suggest that CAP1 serves
as a receptor for resistin in vivo, while also acting as a key phys-
iological regulator of the resistin-induced inflammatory action of
monocytes.
DISCUSSION
Here we identified CAP1 as a resistin receptor that mediates the
proinflammatory effects of human resistin in vitro and in vivo.
The various competitive and direct biochemical binding assays
that were lacking in previous receptor studies validated the
direct interaction between CAP1 and resistin. Moreover, we
have identified the region of CAP1 that binds resistin and pro-
vided structural evidence of the plausibility of the resistin-
CAP1 interaction.
Resistin is part of a unique family of cysteine-rich peptides that
includes resistin-like molecules (RELMs) a and b, raising the
question of whether CAP1 might bind to the RELMs. RELMa is
not conserved in humans (Yang et al., 2003), but in preliminary
studies we found that human resistin-like molecule b (RELMb)
interacts with the same domain of CAP1 that binds resistin (Fig-
ure S3B), andCAP1 had an effect on the production of proinflam-
matory cytokines induced by human RELMb (Figure S3C).CeRELMb is known to contribute to local immune responses in
gut and bronchial epithelial cells (He et al., 2003), and a recent
report showed that RELMb is abundantly expressed in activated
macrophages and contributes to atherosclerosis development
via lipid accumulation and inflammatory facilitation (Kushiyama
et al., 2013). That is similar to the role of resistin in aggravating
atherosclerosis by stimulating monocytes, which is demon-
strated in our previous study (Cho et al., 2011).
In the present study, we further assessed the role of the three
previously reported receptors for resistin: isoform of decorin,
ROR1, and TLR4. The gain- and loss-of-function study demon-
strated that all of the three putative receptors had little effect
on the proinflammatory actions of human resistin in human
monocytes. Furthermore, decorin and ROR1 were scarcely ex-
pressed in human mononuclear cells, and the expression levels
of decorin and ROR1 were not increased, regardless of resistin
treatment. Also, the decorin identified as a potential receptor
was an extracellular cleavage product of decorin, and their
model cell line may not perform the necessary proteolytic cleav-
age. Taken together, our results support that CAP1 is indeed the
bona fide resistin receptor in humans.
With regard to CAP1 localization to the cell membrane, our
detection of CAP1 in the membrane fraction of human mono-
cytes using surface FACS as well as western blotting and
immunofluorescence staining is consistent with an earlier report
that showed that CAP1 is mainly associated with the plasma
membrane in humanmonocytes (Wakeel et al., 2009). Moreover,
we demonstrated that human resistin elicited a change in
CAP1 localization to the membrane surface. As CAP1 lacks a
transmembrane domain, the cell biological mechanism underly-
ing its membrane location is unclear and will require future
investigation.
Resistin and receptor CAP1 upregulated intracellular cAMP
concentration, PKA activity, and NF-kB-related transcription
of many inflammatory cytokines in human monocytes. As a
contributor to the CAP1 receptor signaling that precedes
inflammation, the cAMP/PKA-dependent signaling pathway
might be the key mechanism of the action of resistin, modu-
lating monocytes to lead chronic inflammation. Considering
that resistin was produced by activated monocytes and that
CAP1 was detected in monocytes both in cytosol and near
the plasma membrane, the present study suggests that CAP1
may serve as an autocrine/paracrine receptor or an endoge-
nous receptor for resistin, particularly during inflammatory con-
ditions, so that it can aggravate the inflammatory actions of
monocytes more. Therefore, CAP1 could be a target in the
treatment of inflammatory cardiometabolic diseases, such as
obesity or atherosclerosis.
EXPERIMENTAL PROCEDURES
See also Supplemental Experimental Procedures.
SDS-PAGE Chromatography
To identify the molecule that binds to mFc-conjugated hResistin in THP-1,
which is believed to be a receptor for human resistin, we performed immuno-
precipitation (IP) using mFc-conjugated hResistin protein as a primary
antibody with mFc-specific beads. Briefly, THP-1 cells were incubated with
Human Fc Receptor Binding Inhibitor (Cat. No. 16-9161; eBioscience) for
1 hr to inhibit the nonspecific receptor-mediated binding, and then THP-1ll Metabolism 19, 484–497, March 4, 2014 ª2014 Elsevier Inc. 493
Figure 7. In Vivo Analysis of the Resistin-CAP1 Interaction
(A) The time course of in vivo experiments.
(B) White adipose tissue of humanized resistinmice (CD68hR) fed with a high-fat diet exhibited levels of hResistin, MCP-1, and CAP-1 higher than those of resistin
knockout control mice (R/) (n = 9 for each group; *p < 0.001; ns, not significant). The error bars represent SEM.
(C) Immunohistochemical detection of the monocyte/macrophage-specific antigen CD11b in adipose tissue from humanized resistin and control mice. When
CD68hR mice were systemically infused with monocytes overexpressing CAP1, macrophages heavily infiltrated into the white adipose tissue. When CAP1-
suppressed monocytes were infused instead, macrophages infiltrated the white adipose tissue less heavily (n = 9; yp < 0.01, zp < 0.05). Magnification: upper
panels, 2003; lower panels, 4003. The error bars represent SEM.
(D) Consequently, inflammatory cytokines in white adipose tissuewere inducedmore following systemic administration of CAP1-overexpressingmonocytes than
after administration of CAP1-suppressed monocytes (n = 9; yp < 0.01, zp < 0.05). The error bars represent SEM.
(E) Representative immunofluorescence staining images indicate that infused monocytes migrated to inflamed white adipose tissue and that CAP1-over-
expressing monocytes infiltrated adipose tissue much more heavily than did CAP1-suppressed cells. Scale, 100 mm. See also Figure S5.
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Identification of a Human Resistin Receptorcells were washed with ice-cold PBS, and whole-cell lysates were prepared
with a lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1% Triton X-100,
0.25% sodium deoxycholate, 1mMEDTA, 1mMNaF, and 1mMNa3VO4) con-
taining protease inhibitor cocktail (Roche). The cell lysates were incubatedwith
mFc-conjugated hResistin or recombinant mouse IgG1 Fc (Cat. No. 10690-
MNAH; Sino Biological) as a negative control at 4C on a rotator over-
night. After incubation, the protein complexes were pulled down using
CaptureSelect Multi Species Fc matrix (Bio Affinity Company) and microcen-
trifuged to pellet the protein-mFcmatrix. After washing with PBS, the immuno-
precipitated sample was resuspended with 23 reducing electrophoresis
buffer and boiled at 95C–100C for 5min to denature the protein and separate
it from the protein-mFc matrix. The proteins were separated by electropho-
resis on 8% polyacrylamide SDS gel, and the gel was stained with Coomassie
Brilliant Blue R-250. We found the specific band around the size of 55 kDa only
in the lane of THP-1 whole lysate with mFc-hResistin fusion protein. To identify
this unknown molecule, we excised the band from the gel and performed
MALDI-TOF.
Bimolecular Fluorescence Complementation Assay
HumanCAP1 (bothwild-type andDSH3Dactin BDdeletionmutant) and human
resistin were cloned into pVC155 and pVN173, respectively. pVC155 and
pVN173 were a kind gift from Professor Sunghoe Chang, from Seoul National
University College of Medicine. See the Supplemental Experimental Proce-
dures for more details about lentiviral vector cloning of full-length human
CAP1 and three different deletion mutants of human CAP1. After verifying
sequences, HEK293A cells were transfected with 500 ng of each correspond-
ing BiFC pair using polyethylenimine (PEI). After transfection for 24 hr, cells
were fixed with 2% paraformaldehyde, and fluorescence was imaged with a
confocal microscope (LSM710; Zeiss).
Direct Binding Assay: Surface Plasmon Resonance
The protocol of surface plasmon resonance spectroscopy (SPR) in this study
of real-time direct binding of hResistin and hCAP1 was performed by using a
Biacore X100 (GE Healthcare). The Sensor Chip CM5 with preimmobilized
hResistin (200 ug/ml) in one flow cell was first saturated with hResistin protein.
To analyze the binding kinetics, various concentrations of hCAP1 diluted in
HBS-EP buffer (consisting of 0.01 M HEPES [pH7.4], 0.15 M NaCl, 3 mM
EDTA, 0.005% Surfactant P20) were injected onto the sensor chip for 120 s
at 30 ml/min, and the response unit (RU) was then recorded. After injection of
the analyte was stopped, HBS-EP buffer was poured over the chip for 130 s
at 30 ml/min to allow the bound analytes to dissociate from the immobilized
hResistin, and dissociation curves were obtained. The RU elicited by injecting
HBS-EP buffer was used as the vehicle control. Biacore X100 control software
was used to measure the changes in RU and to plot the binding curve. The
curves obtained from the SPR experiments were analyzed, and the dissocia-
tion equilibrium constant (KD) of hCAP1 to immobilized hResistin was calcu-
lated using kinetic evaluation software. The dissociation equilibrium constant
KD (M) was derived from the equation, KD = kd/ka, where kd and ka are disso-
ciation- and association-rate constants, respectively.
Transwell Migration Assay
Monocyte chemotaxis was measured using a 24-well Micro Transwell Perme-
able Supports (Corning). Wild-type CAP1—and its three different deletion
mutants—overexpressed THP-1 cells, or CAP1, Decorin, TLR4, and ROR1
knockdown THP-1 cells using lentivirus were transferred to the upper chamber
of the microchemotaxis chamber. See Supplemental Experimental Proce-
dures for more details about RNAi and cloning of shRNA constructs. As a
chemoattractant, recombinant human resistin (50 ng/ml) was added to the
lower chamber. The lower and upper chambers were separated by a polycar-
bonate membrane (5 mmpore size). Transmigration was performed for 6–12 hr
at 37C in a humidified atmosphere with 5% CO2. All cells migrating through
the polycarbonate membrane to lower chamber were counted and taken by
light microscopy.
In Vivo Analysis of Resistin-CAP1 Interaction
All animal experiments were performed after receiving approval from the Insti-
tutional Animal Care andUseCommittee (IACUC) of Clinical Research Institute
in Seoul National University Hospital, Korea.CeAge-matched (9- to 10-week-old) male humanized resistin mice expressing
human resistin in their monocyte/macrophage lineages and not expressing
murine resistin (Retn/ CD68hR) were used in this study. Retn/ littermates
were used as controls (R/). All animals were fed a high-fat diet (60% fat,
D12492; Uni-Faith, Inc.) for 1 month, which inducedWAT inflammation. During
this period, excess mononuclear cells (23 108 cells) that either overexpressed
or suppressed CAP1 were infused systemically. To obtain the mononuclear
cells expressing human resistin, we harvested bone marrow and/or spleen
from humanized resistin mice and then isolated the mononuclear cells using
panning procedures and cell sorting. CAP1 expression was modulated by
lentiviral transduction, as described above.
Statistics
All experiments were repeated at least three times, and all data were calcu-
lated as mean ± SEM. In each experiment, biological duplicates or triplicates
were included. Comparisons between groups were performed by Student’s
t test, and the results of in vivo experiments were compared using paired
t tests. SPSS v.11.0 (SPSS) was used for all analyses, and statistical signifi-
cance was assigned at p < 0.05. The error bars represent SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
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